Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ILMN Illumina	$74.78 +4.9%	$88.58	$68.70 ▼ $156.66	$11.85B	1.38	2.27 million shs	3.04 million shs
ILMN Illumina	$74.78 +4.9%	$88.58	$68.70 ▼ $156.66	$11.85B	1.38	2.27 million shs	3.04 million shs
JNJ Johnson & Johnson	$151.62 +2.0%	$159.40	$140.68 ▼ $169.99	$365.39B	0.49	7.95 million shs	9.94 million shs
MRK Merck & Co., Inc.	$79.14 +2.1%	$88.43	$75.96 ▼ $134.63	$199.91B	0.4	11.53 million shs	16.18 million shs
MRNA Moderna	$26.20 +6.9%	$31.56	$23.15 ▼ $170.47	$10.13B	2.23	7.20 million shs	11.00 million shs
UNH UnitedHealth Group	$599.10 +0.8%	$512.87	$438.50 ▼ $630.73	$548.00B	0.61	4.34 million shs	6.12 million shs
XLV Health Care Select Sector SPDR Fund	$136.87 +1.5%	$144.74	$129.66 ▼ $159.64	$36.14B	0.71	7.82 million shs	10.75 million shs
ZBH Zimmer Biomet	$102.30 +0.0%	$106.31	$97.69 ▼ $127.32	$20.36B	0.84	1.63 million shs	2.28 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ILMN Illumina	0.00%	+0.84%	-12.64%	-48.15%	-41.15%
ILMN Illumina	0.00%	+0.84%	-12.64%	-48.15%	-41.15%
JNJ Johnson & Johnson	0.00%	-0.92%	-6.94%	+4.93%	+2.78%
MRK Merck & Co., Inc.	0.00%	-2.87%	-16.45%	-21.60%	-37.06%
MRNA Moderna	0.00%	+4.34%	-24.32%	-25.46%	-75.08%
UNH UnitedHealth Group	0.00%	+14.13%	+22.64%	+10.68%	+36.41%
XLV Health Care Select Sector SPDR Fund	0.00%	+1.18%	-5.56%	-3.24%	-1.47%
ZBH Zimmer Biomet	0.00%	-4.81%	-7.09%	-2.91%	-17.82%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ILMN Illumina	4.6422 of 5 stars	4.2	5.0	0.0	4.2	2.2	1.7	1.3
ILMN Illumina	4.6422 of 5 stars	4.2	5.0	0.0	4.2	2.2	1.7	1.3
JNJ Johnson & Johnson	4.5622 of 5 stars	3.3	3.0	4.2	3.9	2.8	2.5	0.6
MRK Merck & Co., Inc.	5 of 5 stars	4.3	5.0	5.0	3.9	2.6	3.3	3.8
MRNA Moderna	4.2368 of 5 stars	4.0	1.0	0.0	4.6	2.2	2.5	1.3
UNH UnitedHealth Group	4.6191 of 5 stars	2.5	3.0	4.2	4.0	3.4	3.3	1.3
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZBH Zimmer Biomet	4.5991 of 5 stars	3.2	5.0	1.7	3.7	3.0	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ILMN Illumina	2.48	Hold	$138.70	85.48% Upside
ILMN Illumina	2.48	Hold	$138.70	85.48% Upside
JNJ Johnson & Johnson	2.61	Moderate Buy	$171.67	13.22% Upside
MRK Merck & Co., Inc.	2.64	Moderate Buy	$115.50	45.94% Upside
MRNA Moderna	2.04	Hold	$58.70	124.05% Upside
UNH UnitedHealth Group	3.09	Buy	$632.85	5.63% Upside
XLV Health Care Select Sector SPDR Fund	2.78	Moderate Buy	$136.87	N/A
ZBH Zimmer Biomet	2.32	Hold	$124.15	21.36% Upside

Current Analyst Ratings Breakdown

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	UNH UnitedHealth Group	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$610.00 ➝ $660.00
4/10/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$100.00 ➝ $77.00
4/10/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$100.00 ➝ $77.00
4/10/2025	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$171.00 ➝ $159.00
4/9/2025	JNJ Johnson & Johnson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$163.00 ➝ $164.00
4/9/2025	JNJ Johnson & Johnson	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$157.00 ➝ $172.00
4/9/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$39.00 ➝ $32.00
4/9/2025	UNH UnitedHealth Group	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$600.00 ➝ $650.00
4/8/2025	ILMN Illumina	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$128.00 ➝ $112.00
4/8/2025	ILMN Illumina	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$128.00 ➝ $112.00
4/7/2025	ILMN Illumina	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$90.00 ➝ $85.00

(Data available from 4/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ILMN Illumina	$4.37B	2.71	$3.61 per share	20.72	$14.98 per share	4.99
ILMN Illumina	$4.37B	2.71	$3.61 per share	20.72	$14.98 per share	4.99
JNJ Johnson & Johnson	$88.82B	4.11	$12.46 per share	12.17	$29.69 per share	5.11
MRK Merck & Co., Inc.	$64.17B	3.12	$2.75 per share	28.82	$14.85 per share	5.33
MRNA Moderna	$3.20B	3.17	N/A	N/A	$28.33 per share	0.92
UNH UnitedHealth Group	$400.28B	1.37	$38.60 per share	15.52	$106.78 per share	5.61
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A
ZBH Zimmer Biomet	$7.68B	2.65	$13.03 per share	7.85	$62.67 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ILMN Illumina	-$1.22B	-$7.68	N/A	14.49	1.60	-27.95%	13.37%	5.49%	5/8/2025 (Estimated)
ILMN Illumina	-$1.22B	-$7.68	N/A	14.49	1.60	-27.95%	13.37%	5.49%	5/8/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	22.80	13.70	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.73	11.76	7.99	0.77	26.67%	45.35%	17.36%	4/24/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
UNH UnitedHealth Group	$14.41B	$15.50	38.65	18.03	1.37	3.60%	26.69%	8.80%	4/17/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.15	∞	N/A	N/A	N/A	N/A	N/A
ZBH Zimmer Biomet	$903.70M	$4.45	22.99	11.53	1.95	11.77%	12.99%	7.58%	5/5/2025 (Estimated)

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ILMN Illumina	$0.94	N/A	N/A	N/A	$1.03 billion	N/A
5/8/2025	Q1 2025	ILMN Illumina	$0.94	N/A	N/A	N/A	$1.03 billion	N/A
5/5/2025	Q1 2025	ZBH Zimmer Biomet	$1.77	N/A	N/A	N/A	$1.89 billion	N/A
5/1/2025	Q1 2025	MRNA Moderna	-$2.90	N/A	N/A	N/A	$130.35 million	N/A
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	N/A	N/A	N/A	$15.59 billion	N/A
4/17/2025	Q1 2025	UNH UnitedHealth Group	$7.24	N/A	N/A	N/A	$111.56 billion	N/A
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/6/2025	Q4 2024	ILMN Illumina	$0.92	$0.86	-$0.06	$1.17	$1.08 billion	N/A
2/6/2025	Q4 2024	ILMN Illumina	$0.92	$0.86	-$0.06	$1.17	$1.08 billion	N/A
2/6/2025	Q4 2024	ZBH Zimmer Biomet	$2.30	$2.31	+$0.01	$1.20	$2.01 billion	N/A
2/4/2025	Q4 2024	MRK Merck & Co., Inc.	$1.85	$1.72	-$0.13	$1.48	$15.51 billion	$15.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$4.96	3.27%	+5.43%	74.59%	63 Years
MRK Merck & Co., Inc.	$3.24	4.09%	+5.73%	48.14%	14 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
UNH UnitedHealth Group	$8.40	1.40%	+13.46%	54.19%	15 Years
XLV Health Care Select Sector SPDR Fund	$2.34	1.71%	N/A	N/A	N/A
ZBH Zimmer Biomet	$0.96	0.94%	N/A	21.57%	N/A

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/26/2025	ZBH Zimmer Biomet	quarterly	$0.24	0.89%	3/31/2025	3/31/2025	4/30/2025
1/28/2025	MRK Merck & Co., Inc.	quarterly	$0.81	3.32%	3/17/2025	3/17/2025	4/7/2025
2/24/2025	UNH UnitedHealth Group	quarterly	$2.10	1.8%	3/10/2025	3/10/2025	3/18/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ILMN Illumina	0.63	1.77	1.42
ILMN Illumina	0.63	1.77	1.42
JNJ Johnson & Johnson	0.43	1.11	0.86
MRK Merck & Co., Inc.	0.79	1.36	1.15
MRNA Moderna	N/A	3.67	3.62
UNH UnitedHealth Group	0.74	0.83	0.91
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A
ZBH Zimmer Biomet	0.43	1.91	0.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ILMN Illumina	89.42%
ILMN Illumina	89.42%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
MRNA Moderna	75.33%
UNH UnitedHealth Group	87.86%
XLV Health Care Select Sector SPDR Fund	N/A
ZBH Zimmer Biomet	88.89%

Insider Ownership

Company	Insider Ownership
ILMN Illumina	0.17%
ILMN Illumina	0.17%
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.09%
MRNA Moderna	11.00%
UNH UnitedHealth Group	0.33%
XLV Health Care Select Sector SPDR Fund	N/A
ZBH Zimmer Biomet	0.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ILMN Illumina	11,500	158.40 million	158.13 million	Optionable
ILMN Illumina	11,500	158.40 million	158.13 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRK Merck & Co., Inc.	69,000	2.53 billion	2.53 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
UNH UnitedHealth Group	400,000	914.71 million	917.25 million	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	264.07 million	N/A	Not Optionable
ZBH Zimmer Biomet	18,000	199.06 million	197.18 million	Optionable

XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Headlines

Recent News About These Companies

Zimmer Biomet (NYSE:ZBH) & Safe Pro Group Inc. Common Stock (NASDAQ:SPAI) Financial Review

April 14 at 2:33 AM | americanbankingnews.com

Heritage Trust Co Makes New Investment in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 13 at 7:43 AM | marketbeat.com

APG Asset Management N.V. Boosts Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 13 at 5:56 AM | marketbeat.com

Bank of Montreal Can Grows Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 13 at 5:26 AM | marketbeat.com

Bank of Nova Scotia Grows Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 12 at 6:18 AM | marketbeat.com

Legal & General Group Plc Decreases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 12 at 6:01 AM | marketbeat.com

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Invesco Ltd.

April 11 at 6:06 AM | marketbeat.com

Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

April 10, 2025 | prnewswire.com

Aviva PLC Buys 62,507 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 10, 2025 | marketbeat.com

Resona Asset Management Co. Ltd. Invests $6.52 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 10, 2025 | marketbeat.com

Aster Capital Management DIFC Ltd Has $501,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 9, 2025 | marketbeat.com

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Sit Investment Associates Inc.

April 8, 2025 | marketbeat.com

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Schroder Investment Management Group

April 8, 2025 | marketbeat.com

Zacks Research Expects Stronger Earnings for Zimmer Biomet

April 8, 2025 | americanbankingnews.com

Q1 EPS Estimates for Zimmer Biomet Raised by Zacks Research

April 8, 2025 | marketbeat.com

What 5 executives at Zimmer Biomet were paid since 2022

April 7, 2025 | beckersspine.com

ZBH Stock to Gain From Volume Growth Amid Rising Costs

April 7, 2025 | zacks.com

Rhenman & Partners Asset Management AB Purchases New Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 7, 2025 | marketbeat.com

Prudential PLC Purchases 2,936 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 7, 2025 | marketbeat.com

Atlas Capital Advisors Inc. Increases Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 7, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Sells 3,151 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

April 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
3 Defense Stocks Set to Benefit From Increased Military Spending
By Chris Markoch | March 20, 2025
View 3 Defense Stocks Set to Benefit From Increased Military Spending
3 Stocks Near 52-Week Lows With Strong Rebound Potential
By Gabriel Osorio-Mazilli | March 31, 2025
View 3 Stocks Near 52-Week Lows With Strong Rebound Potential
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility
3 Health Insurance Stocks Holding Green in Market Turmoil
By Leo Miller | April 9, 2025
View 3 Health Insurance Stocks Holding Green in Market Turmoil

XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Company Descriptions

Illumina NASDAQ:ILMN

$74.78 +3.52 (+4.94%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$74.37 -0.41 (-0.55%)

As of 04/11/2025 07:52 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Illumina NASDAQ:ILMN

$74.78 +3.52 (+4.94%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$74.37 -0.41 (-0.55%)

As of 04/11/2025 07:52 PM Eastern

Johnson & Johnson NYSE:JNJ

$151.62 +2.93 (+1.97%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$151.68 +0.06 (+0.04%)

As of 04/11/2025 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$79.14 +1.59 (+2.05%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$78.20 -0.94 (-1.19%)

As of 04/11/2025 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna NASDAQ:MRNA

$26.20 +1.70 (+6.94%)

Closing price 04/11/2025 04:00 PM Eastern

Extended Trading

$26.32 +0.12 (+0.46%)

As of 04/11/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

UnitedHealth Group NYSE:UNH

$599.10 +4.70 (+0.79%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$600.00 +0.90 (+0.15%)

As of 04/11/2025 08:00 PM Eastern

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$136.87 +1.98 (+1.47%)

Closing price 04/11/2025 04:10 PM Eastern

Extended Trading

$136.98 +0.11 (+0.08%)

As of 04/11/2025 07:56 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

Zimmer Biomet NYSE:ZBH

$102.30 +0.04 (+0.04%)

Closing price 04/11/2025 03:59 PM Eastern

Extended Trading

$101.45 -0.85 (-0.83%)

As of 04/11/2025 04:35 PM Eastern

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Earnings

Compare Dividends

Latest XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XLV, ILMN, JNJ, UNH, ZBH, MRNA, ILMN, and MRK Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools